Result for
Tag: vaccination
June 15, 2021
COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021
As of May 8, 2021, 16% (22,197 of 135,968) of pregnant women identified in CDC’s Vaccine Safety Datalink, which includes integrated health systems from 7 US states, have received ≥1 dose of a COVID-19 vaccine during pregnancy. Of those initiating vaccination 68% have completed either a 1- or 2-dose series. Vaccination during pregnancy was highest…
June 14, 2021
Community-Level Evidence for SARS-CoV-2 Vaccine Protection of Unvaccinated Individuals
A study of SARS-CoV-2 vaccination in 177 different communities in Israel indicated that for every 20 percentage point increase in the proportion of individuals who were vaccinated in a given population, the positive test fraction for the unvaccinated population decreased approximately two-fold, which the authors suggest shows that vaccination provides indirect protection to unvaccinated individuals. Findings…
Safety Immunogenicity and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-Administered With Seasonal Influenza Vaccines
[Pre-print, not peer-reviewed] As part of the Phase 3 randomized trial for the Novavax SARS-CoV-2 vaccine, a sub-study found that co-administration of an influenza vaccine resulted in no change in influenza vaccine immune response, and a slight reduction in antibody responses to the Novavax vaccine. The authors suggest that this could indicate the viability of…
June 11, 2021
BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 (first identified in India) and B.1.525 (Eta, first identified in Nigeria). Neutralization of all variants, with the exception of B.1.617.1, was only slightly reduced compared to neutralization of wild-type…
June 10, 2021
Optimizing Vaccine Allocation for COVID-19 Vaccines Shows the Potential Role of Single-Dose Vaccination
A model optimizing COVID-19 vaccine allocation calibrated to Washington State found that with high single-dose efficacy (>65%) and low baseline transmission, single-dose vaccination in all adults is optimal and can prevent up to 22% more deaths compared to a strategy prioritizing two-dose vaccination for older adults. However, under low single-dose efficacy (20%) and high transmission…
Antibodies Elicited by mRNA-1273 Vaccination Bind More Broadly to the Receptor Binding Domain than Do Those from SARS-CoV-2 Infection
Vaccine-elicited anti-SARS-CoV-2 antibodies in individuals fully vaccinated with the Moderna vaccine in phase 1/2 trials (n=14) were found to target more epitopes within the receptor binding domain (RBD) when compared to individuals with prior infection. Binding of vaccine-elicited antibodies was more broadly distributed across epitopes compared to infection-elicited antibodies within the RBD, which the authors…
Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar
Travelers fully vaccinated with a COVID-19 mRNA vaccine (n=10,092) had an 87% lower likelihood of having a positive SARS-CoV-2 PCR test upon arrival at Hamad International Airport in Qatar between February and April 2021 compared to travelers with no record of vaccination or prior infection matched 1:1 by age, sex, nationality, and date of testing…
June 8, 2021
Neutralization against B.1.351 and B.1.617.2 with Sera of COVID-19 Recovered Cases and Vaccinees of BBV152
[Pre-print, not peer-reviewed] Sera from individuals fully vaccinated with the inactivated virus SARS-CoV-2 vaccine Covaxin (n=17) showed a 3-fold reduction in neutralizing activity against the B.1.351 (Beta) and B.1.617.2 (Delta) variants of concern compared with the parent D614G variant. Similarly, sera from individuals recovered from COVID-19 showed a 3-fold and 5-fold reduction in neutralizing activity…
Association between Previous Infection with SARS CoV-2 and the Risk of Self-Reported Symptoms after MRNA BNT162b2 Vaccination: Data from 3,078 Health Care Workers
An online questionnaire among healthcare workers vaccinated with the Pfizer-BioNTech vaccine in Italy (n=3,078) found that participants with prior SARS-CoV-2 infection (n=396) had a 3-fold higher risk of moderate systemic symptoms (MSS) after the first dose, but had a 30% lower risk of symptoms after the second dose. MSS was defined as symptoms that either…
June 3, 2021
Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals
The Pfizer-BioNTech vaccine elicited worse local and systemic reactions among individuals with a history of allergy in an online survey of vaccinated medical professionals in Poland (n=1,808). However, no severe allergic reactions were reported. Local redness (17% vs 11%), pain (86% vs 80%), and swelling (19% vs 13%) after the first dose and vomiting (3%…
Next page